Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABVC Biopharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 292% | $58.02M | -7.9x | -0.23 | $3.57 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Metaplanet | OTC Markets | 283.7% | $6.13B | 267.5x | 3.92 | $9.44 | -10.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
IREN Ltd | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 208.6% | $4.08B | -45.5x | 1.98 | $16.88 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
Nuscale Power | NYSE | Utilities | Electrical Utilities & IPPs | 196.4% | $12.22B | -17x | 0.82 | $42.98 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -14.5% Downside | Upgrade to Pro+ | |
D Wave Quantum | NYSE | Technology | Software & IT Services | 150.8% | $5.10B | -27.2x | 2.48 | $16.15 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
Robinhood Markets | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 144.8% | $87.84B | 55.3x | 0.05 | $99.54 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.5% Downside | Upgrade to Pro+ | |
Ast Spacemobile | NASDAQ | Technology | Telecommunications Services | 128.3% | $17.26B | -28.3x | 0.42 | $51.12 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.1% Downside | Upgrade to Pro+ | |
Coinbase Global | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 125.3% | $98.83B | 65.7x | 13.38 | $388.02 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -24.7% Downside | Upgrade to Pro+ | |
51Talk Online Education DRC | NYSE | Academic & Educational Services | Miscellaneous Educational Service Providers | 112.1% | $170.39M | -37x | -0.51 | $29.08 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ProQR Therapeutics NV | NASDAQ | Healthcare | Biotechnology & Medical Research | 107% | $248.61M | -6.2x | 4.31 | $2.36 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Septerna | NASDAQ | Healthcare | Biotechnology & Medical Research | 94.8% | $520M | -3x | 0.06 | $11.67 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 94.8% | $3.14B | -30.1x | -0.98 | $36.76 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -22.7% Downside | Upgrade to Pro+ | |
Yuanbao | NASDAQ | 89% | $1.23B | 6.5x | 0.06 | $27.30 | -9.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Phathom Pharma | NASDAQ | Healthcare | Pharmaceuticals | 79% | $594.80M | -1.6x | 0.11 | $8.54 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Critical Metals Corp | NASDAQ | Basic Materials | Metals & Mining | 77.3% | $413.37M | -1x | $3.99 | 33.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Argo Corp | OTC Markets | Technology | Software & IT Services | 75.2% | $59.63M | -0.07 | $0.44 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Futu | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 74.3% | $20.32B | 24.2x | 0.42 | $145.92 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2% Upside | Upgrade to Pro+ | |
Hims Hers Health | NYSE | Healthcare | Healthcare Providers & Services | 71.3% | $11.29B | 67.1x | 0.01 | $50.46 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.4% Downside | Upgrade to Pro+ | |
CureVac NV | NASDAQ | Healthcare | Biotechnology & Medical Research | 67.5% | $1.22B | 5.8x | 0.04 | $5.41 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4% Downside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | 58.8% | $8.37B | -52.7x | -1.12 | $129.35 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.3% Downside | Upgrade to Pro+ | |
Astera Labs | NASDAQ | Technology | Semiconductors & Semiconductor Equipment | 57.1% | $15.23B | 354.7x | 3.26 | $92.36 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.7% Upside | Upgrade to Pro+ | |
Sailfish Royalty | OTC Markets | Basic Materials | Metals & Mining | 54.6% | $134.67M | 165.4x | 0.92 | $1.78 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DeFi Tech | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 51.9% | $1.09B | 55.8x | 0.4 | $3.28 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NYSE | Technology | Software & IT Services | 51.8% | $26.72B | 232x | 2.16 | $144.80 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.5% Upside | Upgrade to Pro+ | ||
Stoke Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | 51.6% | $641.51M | 13.2x | 0.1 | $11.75 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Up Fintech | NASDAQ | Financials | Investment Banking & Investment Services | 50.5% | $1.81B | 21.6x | 0.24 | $10.26 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
Himalaya Shipping | NYSE | Industrials | Freight & Logistics Services | 45.3% | $304.85M | 20.1x | 0.14 | $6.51 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.3% Upside | Upgrade to Pro+ | |
Gold Royalty | NYSE | Financials | Investment Banking & Investment Services | 45.2% | $415.99M | -124x | -1.46 | $2.44 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.4% Upside | Upgrade to Pro+ | |
Cellectis | NASDAQ | Healthcare | Biotechnology & Medical Research | 44.5% | $149.23M | -3.2x | -0.04 | $2.11 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abivax ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | 40.7% | $583.63M | -0.23 | $8.85 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Elron Electronic Industries | OTC Markets | Financials | Investment Banking & Investment Services | 39.6% | $81.20M | 4.1x | 0.01 | $1.54 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arrowhead Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 37% | $2.43B | -15.5x | -0.24 | $17.63 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dominari Holdings | NASDAQ | Financials | Investment Banking & Investment Services | 35.6% | $76.44M | -0.9x | 0.08 | $5.22 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kuros Biosciences | OTC Markets | Healthcare | Biotechnology & Medical Research | 35.2% | $1.42B | -301.1x | -4.28 | $36.61 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mirum Pharmaceuticals | NASDAQ | Healthcare | Pharmaceuticals | 34.6% | $2.57B | -32.2x | -0.61 | $51.98 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.1% Upside | Upgrade to Pro+ | |
Capital Clean Energy | NASDAQ | Industrials | Freight & Logistics Services | 34.5% | $1.44B | 42.7x | 0.98 | $24.60 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3% Downside | Upgrade to Pro+ | |
Tetragon | OTC Markets | Financials | Collective Investments | 32.6% | $1.40B | 4.2x | $17.20 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Financial 15 | OTC Markets | Financials | Collective Investments | 31.9% | $442.27M | 1.7x | $7.18 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Avadel Pharma | NASDAQ | Healthcare | Pharmaceuticals | 31.2% | $1.01B | -34.3x | -0.43 | $10.38 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NewAmsterdam Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 31.1% | $2.36B | -11.4x | -0.41 | $21.02 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ares Commercial RE | NYSE | Real Estate | Residential & Commercial REITs | 31% | $255.68M | -19.3x | -0.28 | $4.65 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.9% Upside | Upgrade to Pro+ | |
China Fund | NYSE | Financials | Collective Investments | 31% | $153.16M | 7.9x | $15.33 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Volitionrx Ltd | NYSE | Healthcare | Biotechnology & Medical Research | 29.2% | $66.55M | -2.6x | -0.07 | $0.65 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Canadian General Investments | OTC Markets | Financials | Collective Investments | 28.2% | $611.35M | 2.7x | $29.22 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Centessa Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | 27.5% | $2.01B | -7.3x | 0.32 | $15.08 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kr1 | OTC Markets | Financials | Investment Banking & Investment Services | 27% | $66.96M | 6.4x | -0.14 | $0.40 | -11% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
XOMA | NASDAQ | Consumer Cyclicals | Media & Publishing | 26.2% | $314.25M | -36x | -0.47 | $26.26 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regenxbio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | 25.8% | $415.20M | -2.7x | -0.06 | $8.24 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dividend 15 Split | OTC Markets | Financials | Investment Banking & Investment Services | 22.9% | $612.96M | 1.9x | $4.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Perella Weinberg Partners | NASDAQ | Financials | Investment Banking & Investment Services | 22.7% | $1.69B | -94.4x | -1.13 | $19.12 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.6% Upside | Upgrade to Pro+ |